Markets:

Overview

News

Currencies

International

Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

81.74 -0.92 (-1.11%)

Streaming Delayed Price Updated: 1:08 PM EDT, Jul 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

BridgeBio Pharma Touts Encouraging Data From Dwarfism Candidate ↗

July 26, 2022

Via Benzinga

BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial

July 26, 2022

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Posts Promising Data From Gene Therapy Trial In Ultra-Rare Disease ↗

June 22, 2022

Via Benzinga

BridgeBio Pharma Reveals Early Positive Data For Canavan Disease ↗

June 22, 2022

BridgeBio Pharma (NASDAQ: BBIO) announced early positive data from the the first two participants dosed in CANaspire clinical study for the treatment of Canavan disease.

Via Benzinga

BridgeBio Pharma's Return On Capital Employed Insights ↗

May 31, 2022

Benzinga Pro data, BridgeBio Pharma (NASDAQ:BBIO) reported Q1 sales of $1.69 million. Earnings fell to a loss of $201.33 million, resulting in a 32.21% decrease from last quarter.

Via Benzinga

BridgeBio Pharma Posts Early Data From Neurological Movement Disorder Candidate ↗

May 26, 2022

Via Benzinga

Where BridgeBio Pharma Stands With Analysts ↗

May 06, 2022

BridgeBio Pharma (NASDAQ:BBIO) has observed the following analyst ratings within the last quarter:

Via Benzinga

BridgeBio Shares Plunge After it Details Out-Licensing Plans For 'Restructuring Initiative' ↗

May 05, 2022

Via Benzinga

89 Biggest Movers From Friday ↗

June 21, 2022

Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.

Via Benzinga

BridgeBio Pharma Highlights Mid-Stage Study Data Of Acoramidis In Cardiomyopathy Trial ↗

April 04, 2022

BridgeBio Pharma Inc (NASDAQ: BBIO)

Via Benzinga

6 Analysts Have This to Say About BridgeBio Pharma ↗

May 24, 2022

Over the past 3 months, 6 analysts have published their opinion on BridgeBio Pharma (NASDAQ:BBIO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

BridgeBio Partnered Protein Replacement Therapy Shows Promising Action In Painful Skin Blistering Disorder ↗

May 20, 2022

Via Benzinga

The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product ↗

May 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology ↗

May 12, 2022

Via Benzinga

The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More ↗

May 12, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data ↗

March 17, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

What 6 Analyst Ratings Have To Say About BridgeBio Pharma ↗

March 16, 2022

BridgeBio Pharma (NASDAQ:BBIO) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...

Via Benzinga

Where BridgeBio Pharma Stands With Analysts ↗

March 16, 2022

Analysts have provided the following ratings for BridgeBio Pharma (NASDAQ:BBIO) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...

Via Benzinga

BridgeBio Pharma Posts Updated Data From Muscular Dystrophy Trial, Plots Path To Market ↗

March 14, 2022

BridgeBio Pharma Inc (NASDAQ: BBIO) has announced data from the Phase 2 study of BBP-418 in patients with limb-girdle muscular dystrophy type 2i (LGMD2i), a group...

Via Benzinga

Sentynl Buys BridgeBio Pharma's Fosdenopterin Rights In Genetic Disorder ↗

March 08, 2022

BridgeBio Pharma Inc (NASDAQ: BBIO) has agreed to sell Nulibry (fosdenopterin) for injection to Sentynl Therapeutics Inc, owned by Zydus Lifesciences Ltd....

Via Benzinga

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗

March 13, 2022

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...

Via Benzinga

Helsinn, BridgeBio Pharma Amend Infigratinib Pact For Oncology Indications ↗

March 03, 2022

Helsinn Group and BridgeBio Pharma Inc (NASDAQ: BBIO) have updated their existing strategic collaboration to develop, manufacture, and commercialize...

Via Benzinga

Insider Weekends: Co-Founder Of EverQuote Acquires $1.45 Million Worth Of Stock ↗

January 09, 2022

Reviewing the list of companies that were at a new 52 week high and the ones that had hit a fresh 52 week low last week, I was struck by just how many of the companies in the 52...

Via Benzinga

BZ Chart Of The Day: BridgeBio Pharma Teaches Traders Harsh Lesson ↗

January 05, 2022

After a huge move lower, shares of BridgeBio Pharma, Inc. (NASDAQ:

Via Benzinga

40 Biggest Movers From Friday ↗

January 03, 2022

Gainers Nutriband Inc. (NASDAQ: NTRB) shares climbed 157.8% to close at $10.08 on Friday after the company announced the Korean Intellectual Property Office has fully issued its...

Via Benzinga

The Week Ahead In Biotech (Jan. 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week ↗

January 02, 2022

Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. Here are the key catalysts that can sway biotech stocks in the unfolding week.

Via Talk Markets

The Week Ahead In Biotech (Jan 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week ↗

January 02, 2022

Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. On the regulatory front, the Food And Drug Administration...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

December 31, 2021

Gainers Nutriband (NASDAQ:NTRB) stock moved upwards by 186.7% to $11.21 during Friday's regular session. The current volume of 101.5 million shares is 7226.8% of...

Via Benzinga

21 Stocks Moving In Friday's Mid-Day Session ↗

December 31, 2021

Gainers Nutriband Inc. (NASDAQ: NTRB) shares jumped 120.2% to $8.61 after the company announced the Korean Intellectual Property Office has fully issued its patent titled "...

Via Benzinga

3 Stocks Insiders Are Buying ↗

December 31, 2021

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t...

Via Benzinga

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.